• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

腹膜假黏液瘤:疾病进展与微生物因子有关吗?弥漫性腹膜腺黏液瘤和腹膜黏液性癌中细菌、MUC2和MUC5AC表达的研究

Pseudomyxoma peritonei: is disease progression related to microbial agents? A study of bacteria, MUC2 AND MUC5AC expression in disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis.

作者信息

Semino-Mora Cristina, Liu Hui, McAvoy Thomas, Nieroda Carol, Studeman Kimberley, Sardi Armando, Dubois Andre

机构信息

Laboratory of Gastrointestinal and Liver Studies, Department of Medicine, Uniformed Services University and United States Military Cancer Institute, Bethesda, MD 20814, USA.

出版信息

Ann Surg Oncol. 2008 May;15(5):1414-23. doi: 10.1245/s10434-007-9778-9. Epub 2008 Feb 26.

DOI:10.1245/s10434-007-9778-9
PMID:18299935
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2570966/
Abstract

BACKGROUND AND AIMS

Pseudomyxoma peritonei (PMP) is characterized by peritoneal tumors arising from a perforated appendiceal adenoma or adenocarcinoma, but associated entry of enteric bacteria in the peritoneum has not been considered as a cofactor. Because Gram-negative organisms can upregulate MUC2 mucin gene expression, we determined whether bacteria were detectable in PMP tissues.

METHODS

In situ hybridization was performed on resection specimens from five control subjects with noninflamed, nonperforated, non-neoplastic appendix and 16 patients with PMP [six with disseminated peritoneal adenomucinosis (DPAM) and 10 with peritoneal mucinous carcinomatosis (PMCA)]. Specific probes were designed to recognize: (1) 16S rRNA common to multiple bacteria or specific to H. pylori; (2) H. pylori cagA virulence gene; or (3) MUC2 or MUC5AC apomucins. Specimens from one patient with PMCA were examined by ultrastructural immunohistochemistry. Bacterial density and apomucin expression were determined in four histopathological compartments (epithelia, inflammatory cells, stroma, and free mucus).

RESULTS

Enteric bacteria were detected in all specimens. Bacterial density and MUC2 expression were significantly (p < 0.05) higher in PMCA than in DPAM and controls and were highest in free mucin. MUC2 was also expressed in dysplastic epithelia and in associated inflammatory cells. MUC2 expression was significantly correlated with bacterial density.

CONCLUSIONS

Multiple enteric bacteria are present in PMP, and bacterial density and MUC2 expression is highest in the malignant form of PMP. Based on these observations, we propose that the bacteria observed in PMP may play a role in the mucinous ascites and perhaps promote carcinogenesis.

摘要

背景与目的

腹膜假黏液瘤(PMP)的特征是由穿孔性阑尾腺瘤或腺癌引起的腹膜肿瘤,但肠细菌进入腹膜尚未被视为一个辅助因素。由于革兰氏阴性菌可上调MUC2黏蛋白基因表达,我们确定PMP组织中是否可检测到细菌。

方法

对5例非炎症、非穿孔、非肿瘤性阑尾的对照受试者以及16例PMP患者[6例弥漫性腹膜腺黏液瘤(DPAM)和10例腹膜黏液性癌(PMCA)]的切除标本进行原位杂交。设计特异性探针以识别:(1)多种细菌共有的16S rRNA或幽门螺杆菌特异性的16S rRNA;(2)幽门螺杆菌cagA毒力基因;或(3)MUC2或MUC5AC脱辅基黏蛋白。对1例PMCA患者的标本进行超微结构免疫组织化学检查。在四个组织病理学区域(上皮、炎性细胞、基质和游离黏液)中测定细菌密度和脱辅基黏蛋白表达。

结果

所有标本中均检测到肠细菌。PMCA中的细菌密度和MUC2表达显著高于DPAM和对照(p<0.05),且在游离黏液中最高。MUC2也在发育异常上皮和相关炎性细胞中表达。MUC2表达与细菌密度显著相关。

结论

PMP中存在多种肠细菌,且在PMP的恶性形式中细菌密度和MUC2表达最高。基于这些观察结果,我们提出在PMP中观察到的细菌可能在黏液性腹水中起作用,并且可能促进癌变。

相似文献

1
Pseudomyxoma peritonei: is disease progression related to microbial agents? A study of bacteria, MUC2 AND MUC5AC expression in disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis.腹膜假黏液瘤:疾病进展与微生物因子有关吗?弥漫性腹膜腺黏液瘤和腹膜黏液性癌中细菌、MUC2和MUC5AC表达的研究
Ann Surg Oncol. 2008 May;15(5):1414-23. doi: 10.1245/s10434-007-9778-9. Epub 2008 Feb 26.
2
Antibiotic treatment decreases microbial burden associated with pseudomyxoma peritonei and affects β-catenin distribution.抗生素治疗可降低与假性黏液瘤腹膜有关的微生物负担,并影响β-连环蛋白的分布。
Clin Cancer Res. 2013 Jul 15;19(14):3966-76. doi: 10.1158/1078-0432.CCR-13-0616. Epub 2013 Jun 6.
3
MUC2 is a molecular marker for pseudomyxoma peritonei.MUC2是腹膜假黏液瘤的分子标志物。
Mod Pathol. 2002 Sep;15(9):958-72. doi: 10.1097/01.MP.0000026617.52466.9F.
4
Pseudomyxoma peritonei is a disease of MUC2-expressing goblet cells.腹膜假黏液瘤是一种由表达MUC2的杯状细胞引起的疾病。
Am J Pathol. 2002 Aug;161(2):551-64. doi: 10.1016/S0002-9440(10)64211-3.
5
Patients with pseudomyxoma peritonei associated with disseminated peritoneal adenomucinosis have a significantly more favorable prognosis than patients with peritoneal mucinous carcinomatosis.伴有播散性腹膜腺黏液瘤病的腹膜假黏液瘤患者的预后明显优于腹膜黏液腺癌患者。
Cancer. 2001 Jul 1;92(1):85-91. doi: 10.1002/1097-0142(20010701)92:1<85::aid-cncr1295>3.0.co;2-r.
6
Disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to "pseudomyxoma peritonei".播散性腹膜腺黏液瘤病和腹膜黏液性癌病。109例临床病理分析,重点在于鉴别病理特征、起源部位、预后以及与“腹膜假黏液瘤”的关系。
Am J Surg Pathol. 1995 Dec;19(12):1390-408. doi: 10.1097/00000478-199512000-00006.
7
Mucinous tumors arising in ovarian mature cystic teratomas: relationship to the clinical syndrome of pseudomyxoma peritonei.卵巢成熟性囊性畸胎瘤中发生的黏液性肿瘤:与腹膜假黏液瘤临床综合征的关系。
Am J Surg Pathol. 2003 May;27(5):650-7. doi: 10.1097/00000478-200305000-00008.
8
Mucinous ovarian tumors associated with pseudomyxoma peritonei of adenomucinosis type: immunohistochemical evidence that they are secondary tumors.伴有腺黏液瘤病型腹膜假黏液瘤的黏液性卵巢肿瘤:免疫组化证据表明它们是继发性肿瘤。
Int J Gynecol Cancer. 2008 Jan-Feb;18(1):59-65. doi: 10.1111/j.1525-1438.2007.00988.x. Epub 2007 May 19.
9
A core microbiome associated with the peritoneal tumors of pseudomyxoma peritonei.与腹膜假性黏液瘤腹腔肿瘤相关的核心微生物组。
Orphanet J Rare Dis. 2013 Jul 12;8:105. doi: 10.1186/1750-1172-8-105.
10
Mucinous Balls Tangled With Mesothelial Cells and MUC2-Positive Cancer Cells in the Ascites of Pseudomyxoma Peritonei.腹膜假黏液瘤腹水中与间皮细胞和MUC2阳性癌细胞缠结的黏液球
Diagn Cytopathol. 2016 Jul;44(7):628-31. doi: 10.1002/dc.23486. Epub 2016 Apr 15.

引用本文的文献

1
The microbiome of pseudomyxoma peritonei: a scoping review.腹膜假黏液瘤的微生物群:一项范围综述。
Pleura Peritoneum. 2025 May 22;10(2):35-50. doi: 10.1515/pp-2024-0016. eCollection 2025 Jun.
2
Mucin 5AC as a Biomarker for Sessile Serrated Lesions: Results From a Systematic Review and Meta-Analysis.黏蛋白5AC作为无蒂锯齿状病变的生物标志物:系统评价和荟萃分析结果
Clin Transl Gastroenterol. 2025 May 1;16(5):e00831. doi: 10.14309/ctg.0000000000000831.
3
Progress on immuno-microenvironment and immune-related therapies in patients with pseudomyxoma peritonei.

本文引用的文献

1
Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: experience with 501 procedures.细胞减灭术及腹腔内热灌注化疗治疗腹膜表面恶性肿瘤:501例手术经验
J Am Coll Surg. 2007 May;204(5):943-53; discussion 953-5. doi: 10.1016/j.jamcollsurg.2006.12.048.
2
Intracellular, intercellular, and stromal invasion of gastric mucosa, preneoplastic lesions, and cancer by Helicobacter pylori.幽门螺杆菌对胃黏膜、癌前病变及癌症的细胞内、细胞间和基质侵袭。
Gastroenterology. 2007 Mar;132(3):1009-23. doi: 10.1053/j.gastro.2007.01.049. Epub 2007 Jan 31.
3
Extracellular superoxide production by Enterococcus faecalis promotes chromosomal instability in mammalian cells.
腹膜假性黏液瘤患者免疫微环境及免疫相关治疗的研究进展。
Cancer Biol Med. 2024 Jul 18;21(7):586-605. doi: 10.20892/j.issn.2095-3941.2024.0109.
4
Progress in Biological Research and Treatment of Pseudomyxoma Peritonei.腹膜假黏液瘤的生物学研究与治疗进展
Cancers (Basel). 2024 Apr 3;16(7):1406. doi: 10.3390/cancers16071406.
5
Etiological analysis of infection after CRS + HIPEC in patients with PMP.PMP 患者行 CRS + HIPEC 术后感染的病因分析。
BMC Cancer. 2023 Sep 26;23(1):903. doi: 10.1186/s12885-023-11404-1.
6
The Influence of the Microbiome on Metastatic Colorectal Cancer.微生物群对转移性结直肠癌的影响。
Clin Colon Rectal Surg. 2023 Jan 25;36(2):112-119. doi: 10.1055/s-0043-1760864. eCollection 2023 Mar.
7
Current Updates on the Role of Microbiome in Endometriosis: A Narrative Review.微生物群在子宫内膜异位症中作用的最新进展:一项叙述性综述
Microorganisms. 2023 Jan 31;11(2):360. doi: 10.3390/microorganisms11020360.
8
The Role of Microorganisms in Appendiceal Pseudomyxoma Peritonei: A Review.微生物在阑尾假黏液瘤性腹膜假性黏液瘤中的作用:综述。
Curr Oncol. 2022 May 16;29(5):3576-3584. doi: 10.3390/curroncol29050289.
9
New insights in the pathology of peritoneal surface malignancy.腹膜表面恶性肿瘤病理学的新见解。
J Gastrointest Oncol. 2021 Apr;12(Suppl 1):S216-S229. doi: 10.21037/jgo-2020-01.
10
Germline and somatic genetic alterations in two first-degree relatives with appendiceal low-grade mucinous carcinoma peritonei.两名患有阑尾低级别黏液性腹膜癌的一级亲属的生殖系和体细胞基因改变。
Clin Case Rep. 2020 Sep 29;8(12):3168-3177. doi: 10.1002/ccr3.3338. eCollection 2020 Dec.
粪肠球菌产生的细胞外超氧化物会促进哺乳动物细胞中的染色体不稳定。
Gastroenterology. 2007 Feb;132(2):551-61. doi: 10.1053/j.gastro.2006.11.040. Epub 2006 Nov 29.
4
SabA is the H. pylori hemagglutinin and is polymorphic in binding to sialylated glycans.SabA是幽门螺杆菌血凝素,在与唾液酸化聚糖结合方面具有多态性。
PLoS Pathog. 2006 Oct;2(10):e110. doi: 10.1371/journal.ppat.0020110.
5
Recent understanding of IBD pathogenesis: implications for future therapies.炎症性肠病发病机制的最新认识:对未来治疗的启示
Inflamm Bowel Dis. 2006 Nov;12(11):1068-83. doi: 10.1097/01.mib.0000235827.21778.d5.
6
Pseudomyxoma peritonei of appendiceal origin: a clinicopathologic analysis of 101 patients uniformly treated at a single institution, with literature review.阑尾源性腹膜假黏液瘤:对在单一机构接受统一治疗的101例患者的临床病理分析,并附文献综述
Am J Surg Pathol. 2006 May;30(5):551-9. doi: 10.1097/01.pas.0000202039.74837.7d.
7
COX-2 expression in pseudomyxoma peritonei.腹膜假黏液瘤中COX-2的表达
Cancer Lett. 2006 Nov 28;244(1):86-90. doi: 10.1016/j.canlet.2005.12.013. Epub 2006 Jan 19.
8
Isolation of Helicobacter pylori from the intestinal mucosa of patients with Crohn's disease.从克罗恩病患者的肠黏膜中分离出幽门螺杆菌。
Helicobacter. 2006 Feb;11(1):2-9. doi: 10.1111/j.0083-8703.2006.00368.x.
9
Cytoreductive surgery with intraperitoneal chemohyperthermia for the treatment of pseudomyxoma peritonei: a prospective study.细胞减灭术联合腹腔内热化疗治疗腹膜假黏液瘤:一项前瞻性研究。
Dis Colon Rectum. 2005 Jul;48(7):1372-9. doi: 10.1007/s10350-005-0045-5.
10
Interferon gamma induction of gastric mucous neck cell hypertrophy.干扰素γ诱导胃黏液颈细胞肥大。
Lab Invest. 2005 May;85(5):702-15. doi: 10.1038/labinvest.3700260.